Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC

Name: Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC
Published: 2020
License: Public Domain

Telix Pharmaceuticals (Innovations) Pty Limited · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

carcinoma diagnostic-imaging pharmacodynamics pharmacokinetics safety

carcinoma, renal cell, clear cell renal cell carcinoma, pet/ct imaging, 89zr-girentuximab, pharmacokinetics, pharmacodynamics, safety, diagnostic imaging, 89zr-tlx250, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC

Related documents